News
GILD
66.76
+0.91%
0.60
Hepion ends Phase 2 study for NASH drug due to cash restraints
Seeking Alpha · 12h ago
Leap Therapeutics 13G Filing Shows Gilead Sciences, Inc. Reported A 13.9% Stake In The Co As Of April 10, 2024
Benzinga · 12h ago
GILEAD SCIENCES, INC REPORTS 13.9% PASSIVE STAKE IN LEAP THERAPEUTICS AS OF APRIL 10- SEC FILING
Reuters · 12h ago
The Analyst Verdict: Gilead Sciences In The Eyes Of 12 Experts
Benzinga · 14h ago
What to Watch in the Week Ahead and on Monday, April 22
Reuters · 14h ago
Gilead Sciences Is Maintained at Outperform by Oppenheimer
Dow Jones · 18h ago
Gilead Sciences Price Target Maintained With a $105.00/Share by Oppenheimer
Dow Jones · 18h ago
Oppenheimer Maintains Outperform on Gilead Sciences, Maintains $105 Price Target
Benzinga · 18h ago
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
Benzinga · 20h ago
Analysts Are Bullish on These Healthcare Stocks: Gilead Sciences (GILD), Biogen (BIIB)
TipRanks · 21h ago
GILEAD <GILD.O>: BMO CUTS TARGET PRICE TO $80 FROM $89
Reuters · 22h ago
FDA requires labeling changes to CAR-T cell therapies to reflect cancer risk
Seeking Alpha · 23h ago
CORRECTED-U.S. RESEARCH ROUNDUP-Blackstone, Ellington Financial, Netflix
Blackstone, Ellington Financial, Netflix revise their ratings and price targets on several U.S. Companies. Deutsche Bank raises Abbvie Inc target price to $175 from $170, and cuts it to $140 from $145. Blackstone, ellington financial and Netflix also revise their targets on Friday.
Reuters · 1d ago
GILEAD <GILD.O>: LEERINK PARTNERS CUTS TARGET PRICE TO $74 FROM $79
Reuters · 1d ago
US FDA mandates label updates on CAR-T cancer therapies
US FDA mandates label updates on CAR-T cancer therapies that use CAR-t technology. The agency said the changes will highlight the serious risk of T-cell blood cancer in patients who use these therapies. In January, the FDA asked drugmakers to add a boxed warning to their therapies.
Reuters · 1d ago
Gilead Sciences (GILD) Sees a More Significant Dip Than Broader Market: Some Facts to Know
NASDAQ · 1d ago
Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value
Seeking Alpha · 1d ago
ALX Oncology: Trying To Justify The Hype
Seeking Alpha · 1d ago
Stifel starts Mirum at buy, cites IBATi drug potential
Seeking Alpha · 1d ago
Gilead Sciences Price Target Cut to $75.00/Share From $81.00 by UBS
Dow Jones · 1d ago
More
Webull provides a variety of real-time GILD stock news. You can receive the latest news about Gilead Sciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada, Truvada for PrEP, Tybost, Veklury, Vemlidy, Viread, Vosevi, Yescarta and Zydelig. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, and Domvanalimab and zimberelimab, and seladelpar. Seladelpar shall be used for the treatment of primary biliary cholangitis (PBC), including pruritus. The Company operates in more than 35 countries.